Hyderabad: COVAXIN maker Bharat Biotech is on the verge of developing a vaccine against tuberculosis and soon the company will ink an a MoU with another firm for technology.
This was mentioned by Dr. Krishna Ella, CMD Bharat Biotech during BioAsia 2022 Panel Discussion “Our honourable Prime Minister (Narendra Modi) has got an agenda of 2025 for the eradication of tuberculosis. I think we are in that direction. But we don’t have the technology so we are partnering with somebody else. On that matter we should be announcing soon,” Dr. Ella said.
Bharat Biotech to ink MoU for TB Vaccine Technology
Without revealing the details on the name of the firm with which Bharat Biotech will be signing the MoU, Dr. Ella mentioned the TB vaccine is currently undergoing phase 3 clinical trials.
He said the immunology of the nasal vaccine being developed by the company against COVID-19 has been established.
Bharat Biotech earlier last month said BBV154 (Nasal vaccine) received approval for phase 3 clinical trials which will evaluate the jab for both the two-dose primary schedule and booster dose schedule.
